As the Co-Founder and Head of Product Development at PharmaEdge, the end goal is to transform Pharma Competitive Intelligence through innovative AI solutions. Our mission is to revolutionize the industry by streamlining competitive analysis processes, harnessing automation, machine learning and large language models to drive efficiency, and deliver substantial time and cost savings to our clients.In my role, I lead a dynamic team in developing cutting-edge products designed to redefine how pharmaceutical companies access and leverage competitive insights. Our solutions not only enhance decision-making but also set new standards in accuracy and speed.By combining deep industry knowledge with advanced technology, we are committed to reshaping the landscape of Pharma Competitive Intelligence and empowering our clients to stay ahead in a rapidly evolving market.With exceptional talent and cutting-edge tools, there is no need for limits!

1. Strategic Analysis of ImmunotherapiesIn-depth analysis of the Immune-oncology developments and providing detailed reports/ suggestions regarding strategic positioning of immunotherapies across oncology2.Competitive Insight Analysis of Novel MoAsMonthly tracking of Direct/ Indirect competitors of novel early phase assets across oncology & detailed reports visualizing the evolving landscapeDevelopment of TPPs based on current trends in target indications3.Client Interaction & SupportOn the go support for the Non-Financial Value Addition/ Early Phase Asset Development teams of a big pharma company4.Conference Coverage & Primary InteractionDetailed coverage of sessions/ presentations at international conferences & interaction with key scientific/ industry opinion leaders

Healthcare life science consultant specializing in oncology1. Clinical Development Timelines across Oncology (Solid tumors)Analysis of Approved and pipeline agents across solid tumors in terms of their clinical development starting from phase I to approval2. Combination therapy opportunity analysis Identified various opportunities in Oncology for a specific drug combination using scientific rationale, market size, time to market and competitive intensity as filters for prioritization3. Tumor Knowledge Resource DevelopmentDeveloped a comprehensive report for Bladder Cancer & Prostate Cancer which included: Epidemiology, Risk factors, Current tests available, current treatment algorithm, current treatment landscape, emerging treatment landscape, Pricing & cost effectiveness and biomarker segmentation within the indication4. Drug positioning within Prostate Cancer:Suggested go/ no-go for positioning of a drug within prostate cancer by analyzing key differentiators: Efficacy, safety, Viability of Mechanism of Action & Strength of Scientific Rationale5. Training & Tool creation:Working closely with the programming team to create an automated pipeline updating toolCreated an excel based tool for easy launch date calculationTrained colleagues to easily identify, quantify (for epidemiology purposes) and interpret data regarding biomarker status (mutation, amplification etc) in tumors

In vitro assay development, DNA/RNA? protein extraction, Gel electrophoresis and western Blotting, HTS, Free Radical generation and Detection, Flow Cytometry, Comet assay.

Cytotoxicity studies, siRNA silencing, qRT-PCR, Gel electrophoresis and western Blotting, Microscopy, Tissue Culture

Cytotoxicity studies, Gel electrophoresis and western Blotting, Microscopy, Tissue Culture, Microscopy, Scientific Writing, High throughput Screening